Author

M. Garcia-Fabiani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

F. Nunez· 2 shared A. Schwendeman· 1 shared A. Taher· 1 shared C. Gao· 1 shared D. Hambardzumyan· 1 shared D. Li· 1 shared D. Orringer· 1 shared F. M. Nunez· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Nunez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS REVERSES THE MYELOID CELLS'-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT

M. S. Alghamri, R. Avvari, R. Thalla, N. Kamran, L. Zhang, M. Ventosa, A. Taher, S. Faisal, F. Nunez, M. Garcia-Fabiani, S. Haase, S. Carney, D. Orringer, S. Hervey-Jumper, J. Heth, , M. G. Castro

The paper shows that mIDH1 glioma stem cells secrete G-CSF, which reprograms myeloid cells to become non-immunosuppressive, altering the tumor microenvironment.

bioRxiv · Jul 22, 2020 · PreprintCancer Biology

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity

P. Kadiyala, S. V. Carney, J. C. Gauss, M. Garcia-Fabiani, F. Nunez, F. M. Nunez, M. Alghamri, Y. Liu, M. Yu, D. Li, M. Edwards, J. J. Moon, A. Schwendeman, P. R. Lowenstein, M. Castro

This study shows that inhibiting 2-hydroxyglutarate in mIDH1 gliomas with ATRX/TP53 inactivation improves survival and induces anti-tumor immunity through immunological memory and reduced T-cell exhaustion.

bioRxiv · May 11, 2020 · PreprintImmunology